Skip to main content
Clinical Trials/JPRN-UMIN000010695
JPRN-UMIN000010695
Completed
Phase 2

The feasibility study of Oral rehydration therapy for Short hydration in chemotherapy with cisplatin plus gemcitabine for biliary tract cancer - Oral rehydration therapy for Short hydration in chemotherapy with CDDP plus GEM for biliary tract cancer: KHBO1302

Kansai Hepatobiliary Oncology Group (KHBO)0 sites50 target enrollmentMay 13, 2013

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
biliary tract cancer
Sponsor
Kansai Hepatobiliary Oncology Group (KHBO)
Enrollment
50
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 13, 2013
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Kansai Hepatobiliary Oncology Group (KHBO)

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. Patients who received cisplatin previously 2\. Radiological and clinical evidence of pulmonary fibrosis or interstitial pneumonia 3\. Patients with uncontrolled diabetes mellitus or severe liver dysfunction or unstable angina or myocardial infarction within 3 months 4\. Patients with serious infection 5\. Pregnant or lactating female or patients who wish pregnant 6\. Patients having severe allergy 7\. Patients with other serious comorbid diseases 8\. Patients with severe psychological disease 9\. Patients with uncontrollable watery diarrhea 10\. Patients with moderate or severe ascites /pleural effusion 11\. Patients with severe psychological disease 12\. Patients who are positive for a test of hepatitis B virus surface antigen (HBs antigen) without controlled with entecavir 13\. Patients who is judged as an inappropriate case by the investigator

Outcomes

Primary Outcomes

Not specified

Similar Trials